Biosenta Closes Private Placement Financing
Biosenta Closes Private Placement Financing
Toronto, Ontario--(Newsfile Corp. - December 27, 2023) - Biosenta Inc. (CSE: ZRO) (the "Company" or "Biosenta"), is pleased to announce that it has closed its private placement for gross proceeds of $500,000 (the "Offering"), as previously announced on December 15, 2023. Biosenta issued 1,250,000 units (each, a "Unit") under the Offering at a price of $0.40 per Unit, with each Unit consisting of one common share in the capital of the Company (each, a "Common Share") and one half of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles its holder to acquire one common share at a price of $0.80 for a period of 18 months from the closing date of the Offering.
安大略省多倫多--（Newsfile Corp.，2023 年 12 月 27 日）— Biosenta Inc.（CSE: ZRO）（”公司“或 “Biosenta”）很高興地宣佈，它已完成私募配售，總收益爲50萬美元（”提供“），正如先前在 2023 年 12 月 15 日宣佈的那樣。Biosenta 發行了 1,250,000 個單位（每個單元“）根據本次發行，每單位價格爲0.40美元，每個單位由公司資本中的一股普通股組成（每股一股”普通股票“) 以及一份普通股購買權證的一半（每份完整認股權證，a）搜查令“）。每份認股權證的持有人有權在自發行截止之日起的18個月內以0.80美元的價格收購一股普通股。
The securities issued pursuant to the Offering will be subject to a four-month plus one day "hold period" expiring April 29, 2024, as prescribed by applicable Canadian securities laws.
根據適用的加拿大證券法的規定，根據本次發行發行的證券將有四個月加一天的 “持有期”，到2024年4月29日結束。
As a result of closing the Offering, there are 27,656,591 Common Shares of Biosenta issued and outstanding on a non-diluted basis.
本次發行結束後，Biosenta共發行和流通了27,656,591股普通股，未攤薄。
The Company intends to use the net proceeds from the Offering for general corporate purposes.
公司打算將本次發行的淨收益用於一般公司用途。
The Company did not incur any finders' or brokers' fees in connection with the Offering.
公司沒有就本次發行收取任何發現者或經紀人費用。
About Biosenta
關於 Biosenta
Biosenta is a Canadian-based company that develops and manufactures a range of safe and environmentally sound chemical compounds for household and industrial applications.
Biosenta是一家總部位於加拿大的公司，爲家用和工業應用開發和製造一系列安全和環保的化合物。
For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR+).
有關公司的更多詳細信息，請參閱公司在電子文件分析和檢索系統（SEDAR+）上提交的公開文件。
Forward-Looking Statements
前瞻性陳述
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the use of proceeds which is based upon Biosenta's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Biosenta does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Biosenta to predict all such factors.
本新聞稿包含適用的加拿大證券立法所指的 “前瞻性信息”，包括根據Biosenta當前的內部預期、估計、預測、假設和信念以及對未來事件的看法得出的有關所得款項用途的聲明。前瞻性信息可以通過使用諸如 “預期”、“可能”、“將”、“應該”、“打算”、“預期”、“潛在”、“提議”、“估計” 等前瞻性術語和其他類似詞語來識別，包括其負面和語法變體，或關於某些事件或條件 “可能”、“將” 或 “將” 發生的陳述，或通過討論戰略。前瞻性信息包括估計、計劃、預期、觀點、預測、預測、目標、指導或其他非事實陳述的陳述。前瞻性陳述僅爲預期，受已知和未知的風險、不確定性和其他重要因素的影響，這些因素可能導致公司的實際業績或行業業績與未來的業績、業績或成就存在重大差異。任何前瞻性信息僅代表截至發佈之日，除非法律要求，否則Biosenta不承擔任何義務更新或修改任何前瞻性信息，無論這些信息是由於新信息、未來事件還是其他原因造成的。新的因素不時出現，Biosenta不可能預測所有這些因素。
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at including our Management's Discussion and Analysis for the interim period ended June 30, 2023. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
在考慮這些前瞻性陳述時，讀者應牢記我們在SEDAR+上向加拿大相關證券監管機構提交的材料中列出的風險因素和其他警示性陳述，包括我們管理層對截至2023年6月30日的過渡期的討論與分析。這些風險因素和其他因素可能導致實際事件或結果與任何前瞻性信息中描述的事件或結果存在重大差異。
The CSE does not accept responsibility for the adequacy or accuracy of this release.
CSE 對本新聞稿的充分性或準確性不承擔任何責任。
SOURCE Biosenta Inc.
來源 Biosenta Inc.
For further information please contact:
欲了解更多信息，請聯繫：
Am Gill, President and CEO of Biosenta Inc. | Phone: 416-410-2019
Biosenta Inc. 總裁兼首席執行官阿姆·吉爾 | 電話：416-410-2019
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。